CJC-1295 and Ipamorelin Research: GH Axis Signalling and Dual Receptor Studies
Receptor Pharmacology and Mechanism of Action
Ipamorelin GHSR-1a Interactions
Ipamorelin demonstrates selective binding affinity for the growth hormone secretagogue receptor type 1a (GHSR-1a), a class A G-protein coupled receptor. In vitro pharmacological studies utilising competitive radioligand binding assays reveal high-affinity interactions with GHSR-1a, with binding kinetics characterised by nanomolar dissociation constants. Functional cell-based assays demonstrate robust Gq/11 protein coupling, leading to phospholipase C activation and subsequent intracellular calcium mobilisation in transfected cell systems.
The compound exhibits selectivity for GHSR-1a over related receptors, including other ghrelin receptor subtypes and structurally similar GPCRs. Calcium fluorimetric assays in HEK293 cells expressing recombinant GHSR-1a show concentration-dependent responses, with EC50 values typically ranging in the low nanomolar range across multiple independent investigations.
CJC-1295 Growth Hormone-Releasing Hormone Receptor Engagement
CJC-1295 functions as a synthetic analogue targeting the growth hormone-releasing hormone receptor (GHRHR), a class B GPCR coupled to adenylyl cyclase activation. Binding studies demonstrate high-affinity interactions with GHRHR, characterised by extended receptor occupancy due to structural modifications that confer resistance to enzymatic degradation.
In vitro cAMP accumulation assays reveal potent activation of the Gs/adenylyl cyclase pathway in GHRHR-expressing cell models. The compound demonstrates sustained receptor activation profiles compared to native GHRH, with prolonged cAMP elevation observed in time-course studies extending beyond 24 hours in appropriate cell culture systems.
In Vitro Assay Methodologies
Cell-Based Functional Assays
Primary screening methodologies for both compounds employ transfected cell systems expressing target receptors. CHO-K1 and HEK293 cell lines stably transfected with GHSR-1a or GHRHR serve as standard platforms for functional characterisation. Calcium mobilisation assays utilising fluorescent indicator dyes enable real-time monitoring of Gq-coupled responses for ipamorelin studies.
cAMP accumulation measurements through time-resolved fluorescence resonance energy transfer (TR-FRET) or enzyme-linked immunosorbent assay platforms provide quantitative assessment of Gs-coupled signalling for CJC-1295 investigations. Concentration-response relationships are established through serial dilution protocols spanning multiple log units to determine potency parameters.
Binding Kinetics and Competition Studies
Radioligand displacement assays employ tritiated or iodinated reference compounds to assess binding affinity. Competition binding experiments utilise increasing concentrations of test compounds against fixed radioligand concentrations, generating inhibition curves for IC50 determination. Scatchard analysis and saturation binding studies provide insights into receptor density and binding site characteristics in membrane preparations.
Signalling Pathway Analysis
Downstream Effector Systems
Both compounds initiate distinct intracellular cascades through their respective receptor systems. Ipamorelin-mediated GHSR-1a activation triggers phospholipase C-β activation, generating inositol 1,4,5-trisphosphate and diacylglycerol second messengers. This leads to protein kinase C activation and calcium-dependent signalling events measurable through Western blot analysis of phosphorylated substrates.
CJC-1295 engagement of GHRHR results in adenylyl cyclase stimulation and cAMP accumulation, activating protein kinase A and subsequent phosphorylation of cAMP response element-binding protein (CREB). Gene expression profiling reveals upregulation of cAMP-responsive genes in appropriate cell culture models.
Receptor Desensitisation Studies
Extended exposure studies examine receptor desensitisation mechanisms for both compounds. β-arrestin recruitment assays assess GPCR internalisation pathways, while receptor recycling investigations utilise fluorescent receptor constructs to monitor trafficking dynamics in live cell imaging systems.
Combination Research Applications
Dual Pathway Investigations
Research protocols examining concurrent administration of both compounds in cell culture systems reveal potential synergistic interactions at the cellular level. Co-treatment studies in pituitary cell lines demonstrate enhanced signalling responses compared to individual compound treatments, suggesting complementary pathway engagement.
Cross-talk analysis between Gq/11 and Gs pathways examines potential convergence points in downstream signalling networks. Phosphoproteomic approaches identify shared substrate targets and regulatory nodes activated by dual receptor stimulation.
Research Summary
CJC-1295 and ipamorelin represent valuable research tools for investigating growth hormone axis signalling through distinct GPCR pathways. Ipamorelin's selective GHSR-1a targeting via Gq/calcium mobilisation provides insights into ghrelin receptor pharmacology, while CJC-1295's GHRHR engagement through Gs/cAMP activation enables prolonged receptor stimulation studies. Combined investigations reveal complex signalling interactions between these pathways, supporting their utility in comprehensive growth hormone regulatory research applications across diverse cell culture systems and in vitro assay platforms.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML